A Phase 1 Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Subjects With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Jan 2019
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Bone metastases; Prostate cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 14 Sep 2018 Status changed from not yet recruiting to recruiting.
- 24 May 2018 Planned End Date changed from 30 Nov 2020 to 30 Dec 2020.
- 24 May 2018 Planned initiation date changed from 26 Jun 2018 to 2 Nov 2018.